|
The press releases in this section of our website
are presented for achival purposes only, speak only as of their respective
dates and have not been updated.
BIOVEX AGREES SPA WITH THE FDA FOR A PIVOTAL STUDY
WITH ONCOVEXGM-CSF IN METASTATIC MELANOMA
AND ANNOUNCES PRESENTATION OF PHASE II RESULTS AT ASCO
FDA agrees to first SPA for an oncolytic product
Woburn, MA, April 22nd, 2008 – BioVex
Inc, a biotechnology company developing clinical stage treatments
for cancer and the prevention of infectious disease, announced today
that the U.S. Food and Drug Administration (FDA) has approved the
design of a single, pivotal, Phase III clinical trial evaluating
its lead product, OncoVEXGM-CSF in previously
treated patients with metastatic melanoma. The agreement was made
under the special Protocol Assessment (SPA) procedure.
+ read more
BIOVEX TO PRESENT AT THE JPMORGAN 26TH ANNUAL HEALTHCARE CONFERENCE
January 2, 2008 – BioVex Inc today announced that it will
present at the JPMorgan 26th Annual Healthcare Conference at 2:30
p.m. PT on Wednesday, January 9, 2008. The conference is being held
at Westin St. Francis in San Francisco, California.
+ read more
BIOVEX CLOSES SECOND ROUND OF SERIES E FINANCING
Second and Final Close Completes $35 Million Financing
Woburn, MA, November 15 2007 – BioVex
Inc, a clinical stage company developing new generation biologics
for the treatment and prevention of cancer and infectious disease,
announced today it had completed its Series E financing, concurrent
with the completion of a venture debt transaction, raising a total
of $35m of funds.
+ read more
BIOVEX APPOINTS GENZYME EXECUTIVE. JAN VAN HEEK, AS CHAIRMAN OF
THE BOARD OF DIRECTORS
Woburn, MA, October 25th, 2007 – BioVex Inc
announced today that it has appointed Jan Van Heek, age 58, as Chairman
of the Board of Directors.
+ read more
BIOVEX APPOINTS DR LEONARD POST TO THE BOARD OF DIRECTORS
Woburn, MA, September 20th, 2007 – BioVex
Inc announced today that it has appointed Dr. Leonard Post, age 55,
to its Board of Directors.
Press Release September 20 2007
BIOVEX APPOINTS DR THADDEUS PULLANO AS VP,
QUALITY ASSURANCE
Woburn, MA, August 15, 2007
BioVex Inc, a biotechnology company developing clinical stage treatments
for cancer and the prevention of infectious disease, announced today
that it has appointed Dr. Thaddeus Pullano, age 53, as Vice President
of Quality Assurance.
Press Release August 15 2007
BIOVEX RAISES $22 MILLION IN FIRST CLOSE OF
SERIES E FINANCING
Woburn MA July 9 2007
BioVex Inc, a company developing new generation biologics for the
treatment and prevention of cancer and infectious disease, announced
today it had raised $22m in the first close of a series E private
financing.
The placement was led by Triathlon Medical Ventures who were joined
by new investor New Science Ventures as well as existing investors
including ABN Amro (Forbion), Avalon Ventures, Credit Agricole Private
Equity, GeneChem Management of Montreal, Innoven Partners and Scottish
Equity Partners.
Press Release July 9 2007
ONCOVEXGM-CSF CLINICAL TRIALS RESULTS
PUBLISHED
November 21 2006: The results of BioVex's Phase I clinical trial
of OncoVEX GM-CSF in a range of solid
tumors have been published in the November 15 issue of Clinical Cancer
Research (Hu et al : Clin Cancer Res 2006; 12 (22) 6737-6747).
The paper demonstrates that OncoVEX GM-CSF was
well tolerated and could be safely administered using a multi-dose
protocol. Evidence of an antitumor effect was seen. The paper can
be viewed here (by kind permission
of the American Association for Cancer Research). OncoVEX GM-CSF is
now in a Phase II clinical trial (melanoma) and a Phase I/II clinical
trial (head and neck cancer).
top
|
